Table 3.

Univariate and Multivariate Analysis of Factors Associated with Reduction of LSM.

Change LSM	Univariate	R2	P value	Multivariate	R2	P value
Genotype	0.995 (−0.954–2.943)	0.007	0.315
Treatment type	0.164 (−0.993–1.322)	0.000	0.779
Sex (female)	0.167 (−1.474–1.808)	0.000	0.841
Diabetes (present)	−1.043 (−3.430–1.344)	0.005	0.389
Smoking	−0.586 (−4.292–3.119)	0.001	0.755
Age	0.088 (0.021–0.156)	0.041	0.016
Duration of therapy (24 weeks vs 12 weeks)	1.653 (0.033–3.273)	0.023	0.010
Baseline LSM	0.279 (0.216–0.341)	0.330	<0.001	0.260 (0.189–0.331)	0.376	<0.001
Baseline HCV RNA	0.022 (−1.598–1.643)	0.000	0.978
Hemoglobin	−0.473 [−0.850–(−0.095)]	0.037	0.014
Platelet count	−0.023 [−0.033–(−0.014)]	0.122	<0.001	−0.013 [−0.023–(−0.003)]	0.376	0.014
Bilirubin	3.165 (1.400–4.930)	0.001	0.074
Aspartate aminotransferase	0.019 (0.003–0.036)	0.032	0.024
Alanine aminotransferase	0.002 (−0.009–0.013)	0.001	0.738
Alkaline phosphatase	0.005 (−003–0.014)	0.004	0.398
Albumin	−2.633 [−3.745–(−1.522)]	0.122	<0.001
INR	−0.482 (−7.791–6.827)	0.000	0.896
Body mass index	−0.153 (−0.327–0.021)	0.021	0.085	−0.182 [−0.328–(−0.036)]	0.376	0.015
Baseline CAP	−0.003 (−0.018–0.011)	0.001	0.668

Note: LSM, Liver Stiffness Measurement; HCV, Hepatitis C Virus, INR, International Normalized Ratio, CAP, Controlled Attenuation Parameter.